Efficacy of cetuximab in combination with FOLFIRI in a patient with KRAS Wild-type metastatic anal cancer

Case Reports in Oncology

Volumn 5, Issue 2, 2012, Pages 428-433

  Barmettler, Hanna ^a   Komminoth, Paul ^a   Schmid, Mathias ^a   Duerr, Donat ^a  

^a TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Cetuximab; EGFR; FOLFIRI; KRAS; Metastatic anal cancer

Indexed keywords

CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANUS CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; LIVER FAILURE; LIVER METASTASIS; MALE; METASTATIC ANAL CANCER; METASTATIS ANAL CANCER; MULTIPLE CYCLE TREATMENT; PATIENT PREFERENCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 84866858264     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000341371     Document Type: Article

References (15)

1. Siegel R, Ward E, Brawely O, Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomics and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
2. Cummings BJ: Metastatic anal cancer: The search for cure. Onkologie 2006;29:5-6.
3. Jaiyesimi IA, Pazdur R: Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol 1993;16:536-540.
4. Ajani JA, Carrasco CH, Jackson DE, Wallace S: Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 1989;87:221-224.
5. Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F: [5-fluorouracil and cisplatin combination chemotherapy for metastatic squamous-cell anal cancer] Carcinome épidermo'de métastatique de l'anus: étude retrospective de l'efficacité de l'association de 5-fluorouracil en perfusion continue et de cisplatine. Bull Canc 1999;86:861-865.
6. Wanebo HJ, Belliveau J, Begossi G, Levy A: Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer. Colorectal Dis 2003;5:508-514.
7. Tokar M, Bobilev D, Zalmanov S, Geffen DB, Walfisch S: Combined multimodality approach to the treatment of metastatic anal carcinoma: Report of a case and review of the literature. Onkologie 2006;29:5-6.
8. Lukan N, Stroebel P, Willer A, Kripp M, Dinter D, Mai S, Hochhaus A, Hofheinz RD: Cetuximab-based treatment of metastatic anal cancer: Correlation of response with KRAS mutational status. Oncology 2009;77:293-299.
9. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin and cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654.
10. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Lamlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeir U: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373:1525-1531.
11. Van Cutsem E, K'hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
12. Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J, Baert F, Van Laethem JL, Speleman F, Pauwels P, Peeters M: Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010;10:189-197.
13. Zampino MG, Magni E, Sonzogni A, Renne G: K-ras status in squamous cell anal carcinoma (SCC): It's time for target-oriented treatment? Cancer Chemother Pharmacol 2009;65:197-199.
14. Van Damme N, van Roy N, Speleman F, Bols A, van Dorpe J, Pauwels P, Peeters M: EGFR and KRAS gene status evaluation in anal canal squamous cell carcinoma. J Clin Oncol 2008;26(suppl):15569.
15. Celik I, O'Byrne KJ: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from phase 3 FLEX study. Lancet Oncol 2012;13:33-42.